Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.
Registrars:
Capita Registrars
Key Personnel
CEO:
Frank Mathias
CFO:
Lucinda (Lucy) Crabtree
Chairman:
Roch Doliveux
Non-Executive Director:
Colin Bond , Peter Soelkner, Robert Ghenchev, Laurence Espinasse
Senior Independent Director:
Dame Kay Davies
Vice Chairman:
Stuart Henderson
Independent Non-Executive Director:
Heather Preston, Namrata P Patel
Contact Details
Address:
Windrush Court, Transport Way, Oxford, United Kingdom